News Flash

News

Posted on: July 20, 2020

COVID-19 Research, Vaccine Innovations Make GMEP Region a Leader in Pandemic Fight

Kansas State University and faculty in the Biosecurity Research Institute and the College of Veterinary Medicine have conducted important research about how COVID-19 is transmitted and have developed promising vaccine and treatment candidates.

Social-Media-Post_GMEP-Article_COVID (1)

 K-State, Tonix Pharmaceuticals in Early Stage Covid-19 Vaccine Candidate Agreement

Collaborative work among Kansas State University professor of diagnostic pathobiology Waithaka Mwangi, Tonix Pharmaceuticals, the Biosecurity Research Institute and K-State Innovation Partners has resulted in a new preclinical research and option agreement to develop a vaccine candidate for the prevention of COVID-19.

https://www.k-state.edu/media/newsreleases/2020-07/tonix-mwangi-covid71320.html

 

Biosecurity Research Institute, K-State Researchers Confirm Sars-Cov-2 Not Transmitted By Mosquitoes

Stephen Higgs, BRI director and university distinguished professor of diagnostic medicine and pathobiology, with colleagues from BRI and the College of Veterinary Medicine, carried out the first experimental investigation confirming that mosquitoes can’t carry the virus that causes COVID-19.

https://www.k-state.edu/media/newsreleases/2020-07/higgs-mosquitoes-no-covid71720.html


Infectious Disease Expert Details Future Pandemic Research Needs

International zoonotic disease expert and Kansas Board of Regents distinguished professor Juergen Richt has drawn a road map for critical future research on COVID-19. Richt is also researching COVID-19 in livestock and testing potential antiviral drugs in preclinical models.

https://www.k-state.edu/media/newsreleases/2020-05/scientist-offers-assessment-for-covid-19-research.html


K-State, Cocrystal Pharma Ink Promising Research Agreement

Building on their many years of virology research on SARS and MERS, professor Kyeong-ok Chang and associate professor Yunjeong Kim of the K-State College of Veterinary Medicine have developed two protease inhibitors that may lead to possible treatment of the coronavirus infection that causes COVID-19. A licensing agreement now allows Cocrystal Pharma, a clinical-stage biotechnology company, to move forward with preclinical trials of the K-State-patented protease inhibitors.

https://www.k-state.edu/media/newsreleases/2020-04/cocrystal_extend42520.html


To learn more about the Biosecurity Research Institute, its capabilities, mission and job opportunities, visit https://www.bri.k-state.edu/. To learn more about opportunities for private industry to locate near NBAF, BRI or Kansas State University, please contact the Greater Manhattan Economic Partnership.

Facebook Twitter Email

Other News in News